BRCAvantage™ Test Menu

BRCAvantage™ Plus (BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, PALB2)

Test Code: 92587

CPT Code(s): 81162, 81405 (x2), 81479, 81321, 81323, 81406 (x2), 81404

Methodology: Exon Capture • Next Generation Sequencing • Multiplex Ligation-dependent Probe Amplification (MLPA)

Clinical Significance: Approximately 5-10% of breast cancer cases are hereditary. BRCA1 and BRCA2 account for 15-20% of hereditary breast cancers. Five additional breast cancer susceptibility genes include CDH1, PALB2, PTEN, STK11 and TP53. Sequence analysis and deletion/duplication analysis of these five genes can explain an additional 3% to 4.5% of hereditary breast cancers.

BRCAvantage with Reflex to Breat Plus Panel

Test Code: 92573

CPT Code(s): 81162

Includes: If the Interpretation Summary is not one of the following three results: Positive for a known Pathogenic Mutation; Positive for a likely Pathogenic Mutation; Positive for a likely Pathogenic Mutation and a variant with unknown significance, then TP53, PTEN, CDH1, STK11, and PALB2 will be performed at an additional charge (CPT code(s) 81321, 81323, 81404, 81405 (x2), 81406 (x2), 81479).

Methodology: Exon Capture • Next Generation Sequencing • Multiplex Ligation-dependent Probe Amplification

Clinical Significance: 10% of breast cancer cases that are hereditary are caused by a few genes. BRCA1 and BRCA2 account for most (~80%) of hereditary breast cancers. Five other medium risk genes include CDH1, PALB2, PTEN, STK11 and TP53. Sequence analysis and deletion/duplication analysis of these five genes can complement BRCA testing and further elucidate an individual’s hereditary breast cancer risk.

Breast Plus Panel without BRCA (TP53, STK11, PTEN, CDH1, PALB2)

Test Code: 92586

CPT Code(s): 81321, 81323, 81404, 81405 (x2), 81406 (x2), 81479

Clinical Significance: CDH1, PALB2, PTEN, STK11 and TP53 are tumor suppressor genes, where inherited mutations significantly increase breast cancer risk. Sequence analysis and deletion/duplication analysis of these five genes can explain an additional 3% to 4.5% of hereditary breast cancers.

Test FAQ: BRCAvantage Plus Test Menu

Health Plan Coverage:>We are in-network with most national plans and many local plans

Price and Financial Assistance:
The list price of the BRCAvantage® Comprehensive test is $2,495. The Ashkenazi, Single Site, Single Gene and Rearrangement tests are $500 each. List price for BRCAvantage Plus is $3,300 and $805 without BRCA1 and BRCA2.

We provide an easy to use financial assistance program that limits out of pocket expense to $200 for qualified patients with income at or below 400% of the federal poverty level for qualified tests. For patients who do not qualify, we have 0% interest payments plans to help with the cost of testing. Visit BRCAvantage.com for more details.

Concierge Service:
Our team is committed to helping you and your patients navigate the complexities of insurance reimbursement

• Insurance Verification: Upon receipt of a fully completed order and patient specimen, we will verify coverage of your patient’s plan. We will manage this process from beginning to end and take the steps needed for each order. Estimated
• Patient Responsibility:We will estimate your patient’s likely out-of-pocket responsibility at the same time of insurance verification. If the estimated patient responsibility is more than $350, we will attempt to notify you and/or your patient prior to performing the test.

Genetic Counseling:
Our team of genetic counselors is available from 8:30 a.m. to 8:00 p.m. EST by calling 866.GENE.INFO (866-436-3463) to help medical professionals with genetics related questions, including appropriate test selection and interpretation of results. We also connect patients with external genetic counselors as requested and when required by health plans after testing has been ordered.